DK3402820T3 - Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer - Google Patents
Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer Download PDFInfo
- Publication number
- DK3402820T3 DK3402820T3 DK17700926.3T DK17700926T DK3402820T3 DK 3402820 T3 DK3402820 T3 DK 3402820T3 DK 17700926 T DK17700926 T DK 17700926T DK 3402820 T3 DK3402820 T3 DK 3402820T3
- Authority
- DK
- Denmark
- Prior art keywords
- museum
- humanized
- monoclonal antibodies
- chemical anti
- chemical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150808 | 2016-01-11 | ||
| EP16172651 | 2016-06-02 | ||
| PCT/EP2017/050508 WO2017121771A1 (en) | 2016-01-11 | 2017-01-11 | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3402820T3 true DK3402820T3 (da) | 2020-05-18 |
Family
ID=57860833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17700926.3T DK3402820T3 (da) | 2016-01-11 | 2017-01-11 | Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10927173B2 (da) |
| EP (2) | EP3402820B1 (da) |
| JP (2) | JP7099957B2 (da) |
| KR (2) | KR102472087B1 (da) |
| CN (2) | CN108495863B (da) |
| AU (2) | AU2017206631B2 (da) |
| BR (1) | BR112018014028A2 (da) |
| CA (2) | CA3011097C (da) |
| DK (1) | DK3402820T3 (da) |
| EA (1) | EA038880B1 (da) |
| ES (1) | ES2796378T3 (da) |
| HR (1) | HRP20201085T1 (da) |
| IL (2) | IL290425B2 (da) |
| MX (2) | MX2018008558A (da) |
| NZ (1) | NZ744264A (da) |
| PL (1) | PL3402820T3 (da) |
| PT (1) | PT3402820T (da) |
| SG (1) | SG11201805894YA (da) |
| SI (1) | SI3402820T1 (da) |
| WO (1) | WO2017121771A1 (da) |
| ZA (1) | ZA201805337B (da) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3402820T3 (da) | 2016-01-11 | 2020-05-18 | Forty Seven Inc | Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer |
| US20200140565A1 (en) | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| KR102670957B1 (ko) | 2017-07-26 | 2024-05-31 | 포티 세븐, 인코포레이티드 | 항-sirp-알파 항체 및 관련 방법 |
| WO2019020807A1 (en) | 2017-07-28 | 2019-01-31 | Gene Signal International Sa | CD9P-1 TARGETING ANTIBODIES AND USES THEREOF |
| JP7262440B2 (ja) * | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| RU2020109544A (ru) | 2017-08-18 | 2021-09-20 | Ультрахьюман Фор Лимитед | Связывающие агенты |
| US11802153B2 (en) * | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| CA3080860A1 (en) * | 2017-11-01 | 2019-05-09 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 antigen-binding molecules |
| MA51208A (fr) * | 2017-12-01 | 2020-10-07 | Seattle Genetics Inc | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer |
| KR20200119834A (ko) | 2018-02-12 | 2020-10-20 | 포티 세븐, 인코포레이티드 | 항-cd47 및 항-cd20 항체를 이용한 항암 섭생 |
| CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| US20210221908A1 (en) | 2018-06-03 | 2021-07-22 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| EP3817769A4 (en) * | 2018-07-05 | 2022-03-30 | Trican Biotechnology Co., Ltd | HUMAN ANTI-CD47 ANTIBODIES AND THEIR USES |
| US11987627B2 (en) | 2018-08-31 | 2024-05-21 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-CD47 antibody and application thereof |
| CN112105386A (zh) * | 2018-10-31 | 2020-12-18 | 天境生物科技(上海)有限公司 | 新的cd47抗体及其使用方法 |
| TW202104260A (zh) * | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| CA3136450A1 (en) * | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Antibodies that target human cd47 |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021043220A1 (zh) * | 2019-09-03 | 2021-03-11 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599681B (zh) * | 2019-10-25 | 2024-01-09 | 上海药明生物技术有限公司 | 新型抗cd47抗体及其用途 |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| US11845723B2 (en) | 2019-12-24 | 2023-12-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| EP4092051A4 (en) * | 2020-06-18 | 2023-09-06 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd | SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE |
| CN112010979B (zh) * | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人SIRPα单克隆抗体及其用途 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| KR20220080375A (ko) | 2020-12-07 | 2022-06-14 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| AU2021380853B2 (en) * | 2020-12-23 | 2024-10-10 | Guangdong Feipeng Pharmaceutical Co., Ltd. | Antibody targeting CD47 and application thereof |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024522594A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024527335A (ja) | 2021-06-30 | 2024-07-24 | イノベイション バイオ カンパニー リミテッド | Ｃｄ４７に特異的なヒト化抗体およびそれを含むｃｄ４７関連疾患の予防または治療用医薬組成物 |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| IT202100033002A1 (it) * | 2021-12-29 | 2023-06-29 | Diatheva S R L | Anticorpi umani e loro usi |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4245756B1 (en) | 2022-03-17 | 2024-10-09 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023179443A1 (en) * | 2022-03-25 | 2023-09-28 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-her2/anti-cd47 molecules and uses thereof |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| WO2023186067A1 (en) * | 2022-03-31 | 2023-10-05 | I-Mab Biopharma Co., Ltd. | Combination therapies comprising an anti-her2 antibody-drug conjugate for the treatment of cancer |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202400653A (zh) * | 2022-06-21 | 2024-01-01 | 大陸商廣東菲鵬製藥股份有限公司 | 一種含抗cd47抗體或其抗原結合片段的製劑及其製備方法和應用 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| GB9930706D0 (en) * | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| DE60334364D1 (de) | 2002-02-21 | 2010-11-11 | Univ California | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| US8101719B2 (en) | 2003-11-11 | 2012-01-24 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
| US7601355B2 (en) | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| CA2682266A1 (en) | 2007-03-28 | 2008-10-09 | Biogen Idec Inc. | Treatment of hodgkins lymphoma |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| JP4453724B2 (ja) | 2007-06-29 | 2010-04-21 | 株式会社デンソー | 車両用冷凍サイクル装置 |
| JP4148367B1 (ja) | 2007-08-02 | 2008-09-10 | 富山県 | 細胞のスクリーニング方法 |
| CN103242444A (zh) * | 2007-10-11 | 2013-08-14 | 大学健康网络 | 调节SIRPα-CD47相互作用以增加造血干细胞植入和用于此的化合物 |
| DK3043181T3 (da) | 2008-01-15 | 2020-05-04 | Univ Leland Stanford Junior | Markører af akutte myeloid-leukæmi-stamceller |
| CA3170329A1 (en) | 2008-01-15 | 2009-07-23 | Siddhartha Jaiswal | Methods for manilpulating phagocytosis mediated by cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| RS55460B1 (sr) | 2009-11-30 | 2017-04-28 | Janssen Biotech Inc | Mutirana fc antitela sa uklonjenom efektorskom funkcijom |
| EP2569013B1 (en) | 2010-05-14 | 2016-11-23 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| CN107880100A (zh) | 2012-01-17 | 2018-04-06 | 小利兰·斯坦福大学托管委员会 | 高亲和力SIRP‑α试剂 |
| NZ628314A (en) | 2012-02-06 | 2017-01-27 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
| CN110183534A (zh) | 2012-12-03 | 2019-08-30 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| RU2015122228A (ru) | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| CN110066341B (zh) | 2012-12-17 | 2023-01-31 | Pf阿根图姆知识产权控股有限责任公司 | 蛋白、缀合物、药物组合物、DNA构建体、宿主细胞及制备人SIRPα融合蛋白的方法 |
| CA2900468C (en) | 2013-02-06 | 2024-04-30 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN103665165B (zh) | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| CA2939293C (en) | 2014-03-11 | 2023-10-03 | The Board Of Trustees Of The Leland Standford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CN113621075B (zh) | 2014-08-08 | 2024-09-20 | Alx肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| CN104804093A (zh) * | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| IL256989B (en) | 2015-08-07 | 2022-08-01 | Alx Oncology Inc | Constructs with a sirp-alpha site or a variant thereof |
| EP3365370A1 (en) | 2015-10-21 | 2018-08-29 | OSE Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| EP3386545A4 (en) | 2015-12-11 | 2019-06-05 | The Board of Trustees of the Leland Stanford Junior University | ANTICANCER TREATMENT WITH DOUBLE TARGETING OF CD47 AND R-EGF |
| DK3402820T3 (da) | 2016-01-11 | 2020-05-18 | Forty Seven Inc | Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer |
| SG11201806110QA (en) | 2016-01-21 | 2018-08-30 | Univ Leland Stanford Junior | Treatment of cancer with combinations of immunoregulatory agents |
| JP2019511552A (ja) | 2016-04-15 | 2019-04-25 | トリリウム セラピューティクス インコーポレイテッド | Ｃｄ４７遮断療法におけるマクロファージの刺激 |
| KR102670957B1 (ko) | 2017-07-26 | 2024-05-31 | 포티 세븐, 인코포레이티드 | 항-sirp-알파 항체 및 관련 방법 |
| KR20200070341A (ko) | 2017-10-18 | 2020-06-17 | 포티 세븐, 인코포레이티드 | 항-cd47 및 항-pd-l1로 난소암의 치료 |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| KR20200119834A (ko) | 2018-02-12 | 2020-10-20 | 포티 세븐, 인코포레이티드 | 항-cd47 및 항-cd20 항체를 이용한 항암 섭생 |
-
2017
- 2017-01-11 DK DK17700926.3T patent/DK3402820T3/da active
- 2017-01-11 KR KR1020187021469A patent/KR102472087B1/ko active IP Right Grant
- 2017-01-11 JP JP2018537521A patent/JP7099957B2/ja active Active
- 2017-01-11 KR KR1020227041311A patent/KR20220163516A/ko active Application Filing
- 2017-01-11 PT PT177009263T patent/PT3402820T/pt unknown
- 2017-01-11 AU AU2017206631A patent/AU2017206631B2/en active Active
- 2017-01-11 SI SI201730359T patent/SI3402820T1/sl unknown
- 2017-01-11 EP EP17700926.3A patent/EP3402820B1/en active Active
- 2017-01-11 US US16/068,874 patent/US10927173B2/en active Active
- 2017-01-11 CN CN201780006353.4A patent/CN108495863B/zh active Active
- 2017-01-11 CA CA3011097A patent/CA3011097C/en active Active
- 2017-01-11 MX MX2018008558A patent/MX2018008558A/es unknown
- 2017-01-11 CA CA3177526A patent/CA3177526A1/en active Pending
- 2017-01-11 NZ NZ744264A patent/NZ744264A/en unknown
- 2017-01-11 IL IL290425A patent/IL290425B2/en unknown
- 2017-01-11 WO PCT/EP2017/050508 patent/WO2017121771A1/en active Application Filing
- 2017-01-11 ES ES17700926T patent/ES2796378T3/es active Active
- 2017-01-11 PL PL17700926T patent/PL3402820T3/pl unknown
- 2017-01-11 EP EP20172595.9A patent/EP3747906A1/en not_active Withdrawn
- 2017-01-11 CN CN202210449256.5A patent/CN114716552B/zh active Active
- 2017-01-11 SG SG11201805894YA patent/SG11201805894YA/en unknown
- 2017-01-11 EA EA201891435A patent/EA038880B1/ru unknown
- 2017-01-11 BR BR112018014028A patent/BR112018014028A2/pt unknown
-
2018
- 2018-07-11 MX MX2023000781A patent/MX2023000781A/es unknown
- 2018-07-11 IL IL260542A patent/IL260542B/en unknown
- 2018-08-10 ZA ZA201805337A patent/ZA201805337B/en unknown
-
2020
- 2020-07-10 HR HRP20201085TT patent/HRP20201085T1/hr unknown
- 2020-11-20 US US16/953,433 patent/US11643461B2/en active Active
-
2021
- 2021-05-10 AU AU2021202966A patent/AU2021202966B2/en active Active
-
2022
- 2022-05-09 US US17/739,308 patent/US12060423B2/en active Active
- 2022-06-30 JP JP2022106207A patent/JP7375122B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3402820T3 (da) | Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| CL2018000732A1 (es) | Variantes optimizadas de anticuerpos anti-vegf. | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| DK3274366T3 (da) | Kimær antigenreceptor | |
| DK3411404T3 (da) | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner | |
| DK4050034T3 (da) | Cd3-bindende antistoffer | |
| DK3692040T3 (da) | Kemiske forbindelser | |
| DK3411410T3 (da) | Pd-1-antistoffer | |
| DK3331910T3 (da) | Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma) | |
| DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| DK3283110T3 (da) | Antistoffer rettet mod interleukin-36-receptor (il-36r) | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| DK3334457T3 (da) | Humaniserede anti-CCR7-receptorantistoffer | |
| DK3458100T3 (da) | Selektiv reduktion af cystein-manipulerede antistoffer | |
| DK3331553T3 (da) | Hidtil ukendte, antihumane gpvi-antistoffer og anvendelser deraf | |
| DK3116908T3 (da) | Humaniserede kir3dl2-antistoffer | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| CL2017001081S1 (es) | Botella. | |
| DK3456736T3 (da) | Antistofvarianter |